Evoke Pharma — IPO Roadshow (September 2013)
30 slides from Evoke Pharma's IPO roadshow presentation, Sep 3, 2013
Slide 1: Issuer Free Writing Prospectus
Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration No. 333-188838 August 30, 2013 September 2013
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes statements that are, or may be deemed, “forward-looking statements.” In some cases these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” expects,”
Slide 3: Free Writing Prospectus Statement
Free Writing Prospectus Statement This presentation highlights basic information about us and the offering. Because it is a summary, it does not contain all of the information that you should consider before investing. We have filed a registration statement (including a prospectus) with the SEC for
Slide 4: Initial Public Offering Summary
Initial Public Offering Summary Issuer Evoke Pharma, Inc. Exchange / Ticker NASDAQ Capital Market / EVOK Shares Offered 2,100,000 (100% Primary) Over-Allotment 15% or 315,000 (100% Primary) Price Range $12.00 -$14.00 Use of Proceeds Clinical development of EVK-001 and other general corporate purpose
Slide 5: Management
Management Board of Directors • Dave Gonyer, R.Ph.President – & CEO, Founder, Cam Garner (Chairman) and Director Past and current founder, CEO and chairman of several pharma companies – 26 years of pharmaceutical experience in both commercial and product development Todd Brady, M.D., Ph.D. President
Slide 6: Investment Highlights
Investment Highlights • Gastroparesis is common, serious, and currently poorly treated Nasal Delivery Improves • Intranasal delivery avoids GI absorption concerns for patients with Standard of Care for compromised motility Gastroparesis • Predictable absorption regardless of gastric emptying delay a
Slide 7: Gastroparesis Diagnosis & Symptoms
Gastroparesis Diagnosis & Symptoms Undissolved drug tablets in a stomach Symptom flares vary in severity Gastroparesis and diminish interferes with quality of life, GI absorption of negatively impact Simpson, S.E., Clinical Toxicology, 2011 Characteristic food and blood glucose symptoms are medicati
Slide 8: Our novel approach for relief of symptoms of diabetic gastroparesis in women
Our novel approach under development for the relief of symptoms associated with acute & recurrent diabetic gastroparesis in women Intranasal delivery bypasses Sites of drug spray and the gastrointestinal tract absorption and directly enters the bloodstream unlike oral medications Intended to provide
Slide 9: Head to Head Phase 2 Diabetic Gastroparesis Clinical Data
Head to Head Phase 2 Diabetic Gastroparesis Clinical Data (Oral Metoclopramide v. Intranasal Metoclopramide) Mean Total Symptom Score (TSS) Change from Baseline to Week 6 Statistically significant improvement in total symptom score intranasal for doses versus 10 mg oral confirms benefit of intranasa
Slide 10: Gastroparesis Development Landscape
Gastroparesis Development Landscape Development Product Class Route Company Status Dopamine antagonist/ mixed EVK-001 Intranasal Evoke Pharma Phase 3 Ready 5-HT3 antagonist/5-HT 4 agonist Sub Rhythm RM-131 Ghrelin agonist Phase 2 Cutaneous Therapeutics GSK962040 Motilin agonist Oral GlaxoSmithKline
Slide 11: Metoclopramide Nasal Spray (EVK-001) Completed Phase 2b study
Metoclopramide Nasal Spray (EVK-001) for Diabetic Gastroparesis Completed Phase 2b study (METO-IN-002) • US multicenter, double-blind, placebo-controlled study • 287 patients with diabetic gastroparesis • 4-week safety and efficacy study • 3 treatment arms (placebo, 10 mg and 14 mg) • Patient Report
Slide 12: METO-IN-002 Efficacy Results in Women
METO-IN-002 Efficacy Results: Statistical Significant Improvement of Symptoms of Gastroparesis in Women Mean mGCSI-DD Total Score Change from Baseline to Week 4 for Females Summary of Phase 2b Study • Statistically significant difference between EVK-001 and placebo (p<0.02) for the pre-specified ana
Slide 13: METO-IN-002: Gender Disparity in Treatment Effects
METO-IN-002: Gender Disparity in Treatment Effects of EVK-001 vs. Placebo Favors Treatment Favors Placebo Composite Endpoint = Women Nausea* = Men Retching Vomiting Stomach Fullness Efficacy outcomes show Early Satiety* consistent benefit for women across all symptoms Feeling Full Loss of Appetite B
Slide 14: METO-IN-002: Favorable Safety Profile
METO-IN-002: Favorable Safety Profile Treatment-Emergent Adverse Events Reported by More than 2 Subjects in Any Treatment Group Summary of Data Placebo EVK-001 10 mg IN EVK-001 14 mg IN (N = 95) (N = 95) (N = 95) • EVK-001 was well-tolerated at both Dysgeusia* 4 (4.2%) 12 (12.6%) 13 (13.7%) the 10 m
Slide 15: End of Phase 2 Regulatory Guidance
End of Phase 2 Regulatory Guidance • Required for NDA filing – Single Phase 3 study in women only • Dose, regimen, duration (10 mg, QID, and 28 days), and endpoint – Thorough QT study • Despite the absence of cardiac safety issues with metoclopramide • Not required for NDA filing – Parallel study in
Slide 16: Planned Phase 3 Study for EVK-001
Planned Phase 3 Study for EVK-001 • Demonstrate safety and effectiveness of metoclopramide Objective nasal spray versus placebo in reducing the symptoms of gastroparesis • Double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and population pharmacokinetics in adult
Slide 17: Planned Development Timeline
Planned Development Timeline METO-IN-003 (female study) Top-Line Pivotal Phase 3 Data METO-IN-004 (male study) Not Required for NDA Filing Top-Line TQT Study Data 17
Slide 18: Compelling Commercial Opportunity
Compelling Commercial Opportunity • Physician market research indicates significant need and positive feedback for EVK-001 – Gastroenterologists, Internal Medicine, and Primary Care – Over 300 physicians • Payer and pricing research shows potential rapid market uptake – Large and mid size plans – Me
Slide 19: US Gastroparesis Population is Large and Growing
US Gastroparesis Population is Large and Growing • Potentially 12-16 million patients with symptoms of gastroparesis • Many patients go untreated 80% 80% of all patients diagnosed with gastroparesis are women • Samsom M, Roelofs J. “Prevalence of Delayed Gastric Emptying in Diabetic Patients and Rel
Slide 20: 50%-80% of Patients Are Already Treated with Metoclopramide
50% -80% of Patients Are Already Treated with Metoclopramide, Trending Higher in Moderate to Severe Patients Metoclopramide Share Mild to moderate patients Moderate to severe patients 100% 100% 75% 75% 9% 6% 7% 8% 5% 6% 50% 50% 50% 47% 48% 41% 39% 38% 25% 25% 20% 15% 14% 17% 15% 14% 0% 0% Overall, H
Slide 21: Physicians Are Not Satisfied with Current Treatment Options
Physicians Are Not Satisfied with Current Treatment Options View of Current Medications I am concerned about safety issues associated with the delayed absorption and the potential 5.5 of multiple medications administered throughout the day There is a need in I am concerned about patients absorbing g
Slide 22: MDs' Concerns Regarding Absorption Are Addressed by EVK-001
MDs’Concerns Regarding Absorption of Medication Are Addressed by EVK-001’s Base Product Profile Mode of Delivery Attributes 6.1 IN metoclopramide may allow patients with 6.1 vomiting to absorb the medication 6.2 Total 5.9 IN delivery may provide faster absorption 5.9 GE compared to oral 5.9 PCP 5.8
Slide 23: Patients Prefer Nasal Delivery and Will Use It If Prescribed
Gastroparesis Patients Have Previous Experience, Prefer Nasal Delivery and Will Use It If Prescribed Patient Preferences Source: G&S Research, May 2011. N = 98. All previously diagnosed with diabetic gastroparesis and enrolled in METO-IN-002. Questions: 31, 37, 38, 35 23
Slide 24: EVK-001 Payer Reimbursement Landscape
EVK-001 Payer Reimbursement Landscape Commercial Predicted Formulary Access of EVK-001 (n = 10; 104M total US lives represented) SE = electronic step edit PA = prior authorization QL = quantity limits Increasing price points As the majority of patients are already on generic metoclopramide, a step e
Slide 25: Limited Treatment Options Creates Underserved and Large Market
Limited Treatment Options for Gastroparesis Creates Underserved and Large Market • Only approved product approved in the US for diabetic gastroparesis First line treatment (AGA guidelines) Metoclopramide • Boxed warning in 2009 (generic) • ~ 5 M Rx’s/year Oral & IV Propulsid ® (cisapride) • Not appr
Slide 26: EVK-001 Intellectual Property Summary
EVK-001 Intellectual Property Summary IP Landscape U.S. Granted Patents Patent # U.S. 6,770,262 U.S. 8,334,281 • Two (2) key issued U.S. Title Nasal Administration of Agents for Nasal Formulations of patents covering method the Treatment of Gastroparesis Metoclopramide of use and formulation Expires
Slide 27: Valuation Comparables
Valuation Comparables Company Stage Asset Valuation Evoke Pharma $77M Phase 3 Optimized drug for Gastroparesis (EVOK) (post midpoint money) Synergy Pharma Phase 3 NCE for IBS $400M (SYGP) Ironwood Pharmaceuticals Commercial NCE for IBS $1.2B (IRWD) Santarus Optimized drug for Crohn’s & Commercial $1
Slide 28: Pre-IPO Capital Structure
Pre-IPO Capital Structure Capitalization Shares Outstanding% Outstanding Common Stock 3,681,752 96.20% 1 StockOptions 123,250 3.22 % 2 Warrants 22,000 0.57 % Fully-diluted Shares Outstanding 3,827,002 100 % 1 Averagestrikepriceof $0.40 2 Averagestrikepriceof $7.50 28
Slide 29: IPO – Use of Proceeds and Next Steps
IPO –Use of Proceeds and Next Steps • Research & Development$15M - – Complete one Phase 3 clinical trial of EVK-001 for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adult women with diabetes mellitus – Complete a Thorough QT study for EVK-001 – Begin a paralle
Slide 30: Investment Highlights
Investment Highlights • Gastroparesis is common, serious, and currently poorly treated Nasal Delivery Improves • Intranasal delivery avoids GI absorption concerns for patients with Standard of Care for compromised motility Gastroparesis • Predictable absorption regardless of gastric emptying delay a